Kim Blickenstaff

Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA.

Respiratory Motion, Inc. develops medical devices. The firm specializes in clinical research, clinical evaluation and testing. Its product ExSpiron 1Xi, measures minute ventilation non-invasively. The company was founded by Jenny E. Freeman, Alexander Panasyuk and Svetlana Panasyuk in March 2010 and is headquartered in Waltham, MA.

Founded in 1996, Amira Medical develops and markets glucose monitoring products. In particular, it has pioneered proprietary technology to enable users to draw a small blood sample from areas of the body other than the fingertips

SenoRx, Inc. develops and manufactures invasive devices for the diagnosis and treatment of breast cancer. The company was founded in 1998 and is headquartered in Tempe, AZ.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY.

OPY Acquisition Corp. I is blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded July 20, 2020 and is headquartered in New York, NY.